Promatix
Promatix Biosciences Ltd is a UK-based preclinical biotech developing cis-bispecific antibody-drug conjugates for solid tumours using a proprietary proteomics-driven discovery platform, with its lead EGFR × EphA2 program targeting colorectal cancer under a pre-revenue licensing and pharma-partnership model.
- Company typePrivate
- Founded2020
- HeadquartersLondon, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Promatix does
Promatix Biosciences Ltd is a UK-based, pre-clinical-stage biotechnology company developing next-generation bispecific antibody-drug conjugates (ADCs) for solid tumours. The company is built on an integrated proprietary discovery platform (TxPro + CipherPro + AviPro + BiPro) that combines large-scale tumor surface proteomics (the surfaceome) with Boolean logic-gated computational modelling to identify complementary antigen pairs for cis-bispecific AND-gate targeting. The platform has catalogued bispecific assets tuned for eighteen common cancer types and identified more than 2,000 potential cis-bispecific combinations meeting strict differential expression criteria, compared to only 24 monospecific targets from the same 2,768-protein dataset. The lead program, PBS293-exatecan (EGFR × EphA2 cis-bispecific ADC), is being advanced through IND-enabling studies for colorectal cancer, with planned expansion into oesophageal cancer and non-small cell lung cancer; preclinical data for the closely related PBS293-MMAE construct demonstrated 50-fold greater potency than cetuximab-MMAE in KRAS-mutant HCT116 colorectal cells and sparing of normal keratinocytes.
The company is pre-revenue and pursues a licensing and co-development business model, targeting global pharmaceutical partners for late-stage development and commercialisation of its ADC candidates. Current funding consists of a non-dilutive Innovate UK Biomedical Catalyst grant (July 2026) supporting the PBS293-exatecan IND-enabling workstream, executed through CRO partnerships with Abzena, Crown Bioscience, and Labcorp UK. The company was co-founded by Dr. Mick Hunter (CEO), Dr. Mark Edwards (CTO), and Dr. Roy Pettipher (CSO), with Dr. Graeme Martin as Executive Chairman; the leadership team has a track record of prior transactions including Atopix (sold to Chiesi, 2016) and the ROR gamma licensing to AstraZeneca via Orca Pharmaceuticals. Operations are headquartered in London (78 Pall Mall) with laboratory facilities at Babraham Research Campus, Cambridge, and headcount is in the 1–10 range. A Series A financing is planned to transition the lead program into clinical development.
Promatix firmographics
Firmographics- Name
- Promatix
- Legal name
- Promatix Biosciences Ltd
- Website
- https://pro-matix.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Promatix Biosciences Ltd is a UK-based preclinical biotech developing cis-bispecific antibody-drug conjugates for solid tumours using a proprietary proteomics-driven discovery platform, with its lead EGFR × EphA2 program targeting colorectal cancer under a pre-revenue licensing and pharma-partnership model.
- Ownership category
- akta.pro rank
Promatix industry classification
Industry- Product category
- Oncology ADC Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)
- akta.pro secondary industries
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Proteomics & Biomarker Analytical Testing (HLAGADAG)
Keywords
Where Promatix is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Promatix business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Licensing and Co-development: Pre-revenue biotech company expected to generate value through licensing agreements and strategic partnerships with pharmaceutical companies for late-stage development and commercialization of bispecific ADC candidates. The company plans to pursue pharma partnerships and Series A financing to fund pipeline development.
- Non-dilutive Grant Funding: Company has secured non-dilutive Innovate UK Biomedical Catalyst grant funding to support preclinical development of lead program PBS293-exatecan without equity dilution.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Promatix product offering
Product offeringCore offering
Promatix is a UK-based pre-clinical biotechnology company developing next-generation cis-bispecific antibody-drug conjugates (ADCs) for the treatment of solid tumours. Its proprietary proteomics-driven discovery platform combines large-scale tumour surface proteomics with logic-gated computational modelling to identify complementary antigen pairs for AND-gate targeted ADCs. Lead programmes include PBS293-MMAE and PBS293-exatecan, which co-target EGFR and EphA2 in indications such as colorectal cancer and other solid tumours.
Product overview
Promatix is an emerging UK-based biotechnology company developing next-generation bispecific antibody-drug conjugates (ADCs) through its integrated discovery platform. The Promatix Platform combines four proprietary components: TxPro (cancer proteomics database), CipherPro (computational algorithms for target mining), AviPro (in silico affinity engineering), and BiPro (functional validation pipeline). The platform identifies optimal combinations of cancer surface markers for cis-bispecific AND-gate targeting, where strong binding occurs only when two distinct antigens are present on the same tumour cell. Lead programs include PBS293-MMAE and PBS293-exatecan, first-in-class EGFR × EphA2 cis-bispecific ADCs for colorectal cancer and other solid tumours, with additional pipeline candidates identified for eighteen common cancer types.
Differentiator
Problem solved
Functional benefit
Products and services
- PBS293-MMAE Pre-clinical cis-bispecific antibody-drug conjugate (ADC) lead candidate co-targeting EGFR and EphA2 with MMAE payload; designed for AND-gate tumour selectivity and intended for licensing or co-development by pharmaceutical partners targeting colorectal and other solid tumours.
- PBS293-exatecan Second lead cis-bispecific ADC from the PBS293 programme co-targeting EGFR and EphA2, this time with an exatecan (topoisomerase I inhibitor) payload; provides payload diversification for out-licensing to pharma partners.
Quantifiable outcome
- PBS293-MMAE demonstrated 50-fold greater potency than cetuximab-MMAE in HCT116 colorectal cancer cells (low-nanomolar potency)
- +2 more outcomes
Companies that use Promatix
Customer profileSegments2 records
Ideal customer profiles2 records
Promatix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature4 records
Promatix partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- AbzenacoreUK-based contract research organization engaged for PBS293-exatecan development program under Innovate UK Biomedical Catalyst grant. Abzena provides manufacturing scale-up and conjugation services for the lead bispecific ADC candidate.
- Crown BiosciencecoreContract research organization providing preclinical proof-of-concept studies using both cell-line-derived (CDX) and patient-derived (PDX) xenograft models for PBS293-exatecan colorectal cancer program.
- Labcorp UKcoreContract research organization engaged for IND-enabling regulatory safety studies for PBS293-exatecan, providing the industry-standard data package expected for ADC development candidates.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Promatix competitors and assessment
Company assessmentBroad incumbents
- AstraZeneca: Global pharma with major ADC investments (Datroway, Enhertu via partnership with Daiichi Sankyo). Already a counterparty in multiple Promatix-adjacent transactions (KuDOS, Spirogen, Orca ROR gamma).
- Daiichi Sankyo: Global pharma leader in ADCs with Enhertu and Datroway. While far larger, Daiichi Sankyo represents the kind of pharma partner Promatix would target and the competitive bar its platform must clear.
- Genmab: Established biotech with proprietary bispecific antibody platforms (DuoBody, HexaBody) and a partnership-driven pipeline. Comparable as a broader antibody platform player whose technologies are licensed to large pharma partners.
Direct peers
- Zymeworks: Clinical-stage biotech developing bispecific antibodies and bispecific ADCs using its Azymetric and Zanidatamab platforms. Direct peer in the bispecific ADC space with a comparable platform-plus-pipeline business model.
- ADC Therapeutics: Clinical-stage oncology biotech developing proprietary ADCs including loncastuximab tesirine. Direct peer in the ADC space, and Promatix's BD Director Richard Onyett joined Promatix directly from ADC Therapeutics in 2025, indicating close industry overlap.
Emerging players
- Mersana Therapeutics: Clinical-stage biotech developing novel ADCs with proprietary payloads and linkers (Dolasynthen, Immunosynthen platforms). Comparable as a small, platform-driven ADC company pursuing strategic pharma partnerships to advance its pipeline.
- Pyxis Oncology: Clinical-stage biotech developing antibody-drug conjugates and immunotherapies. Comparable as a small-cap ADC developer targeting solid tumours with tumour-selective approaches.
- CytomX Therapeutics: Clinical-stage biotech developing conditionally activated ADCs and other biologics (Probody platform). Comparable as a platform-based ADC developer targeting improved tumour selectivity through engineered antibody formats.
- Tubulis: German biotech developing differentiated ADCs with proprietary conjugation chemistry and linkers. Comparable as a European pre-clinical/early-clinical ADC platform company focused on tumour selectivity and therapeutic index.
- Innovent Biologics: China-headquartered biotech with a growing ADC and bispecific antibody pipeline. Comparable as an emerging player investing in novel ADC formats and bispecific tumour-selective targeting approaches.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Promatix social profiles
Digital presencePromatix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Promatix leadership team
Management profileNumber of profiles
Promatix funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Promatix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Promatix
What does Promatix do?
Promatix is a UK-based pre-clinical biotechnology company developing next-generation cis-bispecific antibody-drug conjugates (ADCs) for the treatment of solid tumours. Its proprietary proteomics-driven discovery platform combines large-scale tumour surface proteomics with logic-gated computational modelling to identify complementary antigen pairs for AND-gate targeted ADCs. Lead programmes include PBS293-MMAE and PBS293-exatecan, which co-target EGFR and EphA2 in indications such as colorectal cancer and other solid tumours.
Is Promatix a public or private company?
Promatix is a private company. It is classified as venture growth investor backed and is currently operating.
When was Promatix founded?
Promatix was founded in 2020. It employs 1 to 10 people.
Where is Promatix based?
Promatix is headquartered in London, United Kingdom, in the Europe region.
How does Promatix make money?
Two revenue lines are on record. Licensing and Co-development is the primary driver. The others are non-dilutive Grant Funding.
Who are Promatix's main competitors?
Broad incumbents on record are AstraZeneca, Daiichi Sankyo and Genmab. Direct peers are Zymeworks and ADC Therapeutics. Emerging players are Mersana Therapeutics, Pyxis Oncology, CytomX Therapeutics, Tubulis and Innovent Biologics.
Does Promatix have an API?
No public API is recorded for Promatix.
What industry is Promatix in?
Promatix's product category is Oncology ADC Drug Discovery. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 2836.